Linked Life Data

2557881

Source:http://linkedlifedata.com/resource/pubmed/id/2557881

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1990-2-20
pubmed:abstractText
In a prospective trial of 75 Chinese patients with histologically proven inoperable hepatocellular carcinoma (HCC), 25 patients were randomised to receive doxorubicin 60-75 mg m-2 intravenously once every 3 weeks, 25 to receive recombinant alpha 2 interferon (rIFN) (Roferon) 9-18 x 10(6) IU m-2 intramuscularly (i.m.) daily and 25 to receive rIFN 25-50 x 10(6) IU m-2 i.m. three times weekly. Patients were switched to the other drug if: (a) there was progressive disease after 12 weeks, (b) unacceptable toxicity developed and (c) they had received a total of 500 mg m-2 of doxorubicin. Six patients had switching over of therapy, three on doxorubicin and three on rIFN. In the remaining 69 patients on single drug therapy, the median survival rate of patients on doxorubicin and rIFN was 4.8 and 8.3 weeks respectively (P = ns.). rIFN induced tumour regression of 25-50% in 12% of patients and of over 50% in 10% of patients. When compared with doxorubicin, rIFN was associated with more tumour regression (P = 0.00199) and less progressive tumours (P = 0.00017). It caused less prolonged and less severe marrow suppression (P = 0.01217), and had significantly less fatal complications than doxorubicin (P = 0.01383). Doxorubicin caused fatal complications due to cardiotoxicity and neutropenia in 25% of patients. rIFN was associated with fatal complications due to dementia and renal failure in 3.8% of patients. In the treatment of inoperable HCC, rIFN is superior to doxorubicin in causing more tumour regression, less serious marrow suppression and less fatal complications.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/2557881-2449110, http://linkedlifedata.com/resource/pubmed/commentcorrection/2557881-2461890, http://linkedlifedata.com/resource/pubmed/commentcorrection/2557881-2839280, http://linkedlifedata.com/resource/pubmed/commentcorrection/2557881-2890808, http://linkedlifedata.com/resource/pubmed/commentcorrection/2557881-2990514, http://linkedlifedata.com/resource/pubmed/commentcorrection/2557881-2990662, http://linkedlifedata.com/resource/pubmed/commentcorrection/2557881-3013985, http://linkedlifedata.com/resource/pubmed/commentcorrection/2557881-6266641, http://linkedlifedata.com/resource/pubmed/commentcorrection/2557881-6277763, http://linkedlifedata.com/resource/pubmed/commentcorrection/2557881-6322986, http://linkedlifedata.com/resource/pubmed/commentcorrection/2557881-6748198, http://linkedlifedata.com/resource/pubmed/commentcorrection/2557881-7369106
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:volume
60
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
928-33
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.
pubmed:affiliation
Department of Medicine, University of Hong Kong, Queen Mary Hospital.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial